Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin

References

• GattaGvan der ZwanJMCasaliPGRare cancers are not so rare: the rare cancer burden in EuropeEur J Cancer201147172493251122033323
   PubMed Web of Science ®Google Scholar
• ClarkMAFisherCJudsonIThomasJMSoft-tissue sarcomas in adultsN Engl J Med2005353770171116107623
   PubMed Web of Science ®Google Scholar
• FletcherCDUnniKKMertensFWHO Classification of Tumours of Soft Tissue and BoneLyon, FranceIARC Press2013
   Google Scholar
• SmithSMColemanJBridgeJAIwenofuOHMolecular diagnostics in soft tissue sarcomas and gastrointestinal stromal tumorsJ Surg Oncol2015111552053125772665
   PubMed Web of Science ®Google Scholar
• TuckerMAD’AngioGJBoiceJDJrBone sarcomas linked to radiotherapy and chemotherapy in childrenN Engl J Med1987317105885933475572
   PubMed Web of Science ®Google Scholar
• RubinoCShamsaldinALeMGRadiation dose and risk of soft tissue and bone sarcoma after breast cancer treatmentBreast Cancer Res Treat200589327728815754127
   PubMed Web of Science ®Google Scholar
• YoungRJBrownNJReedMWHughesDWollPJAngiosarcomaLancet Oncol2010111098399120537949
   PubMed Web of Science ®Google Scholar
• SchulzTFCesarmanEKaposi Sarcoma-associated Herpesvirus: mechanisms of oncogenesisCurr Opin Virol20151411612826431609
   PubMed Web of Science ®Google Scholar
• BremsHBeertEde RavelTLegiusEMechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1Lancet Oncol200910550851519410195
   PubMed Web of Science ®Google Scholar
• RyanCWDesaiJThe past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcomaAm Soc Clin Oncol Educ Book2013
   Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• LinchMMiahABThwayKJudsonIRBensonCSystemic treatment of soft-tissue sarcoma-gold standard and novel therapiesNat Rev Clin Oncol201411418720224642677
   PubMed Web of Science ®Google Scholar
• PangACarbiniMMakiRGContemporary therapy for advanced soft-tissue Sarcomas in adults: a reviewJAMA Oncol Epub552016
   Web of Science ®Google Scholar
• BramwellVHAndersonDCharetteMLDoxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcomaCochrane Database Syst Rev20033CD00329312917960
   PubMedGoogle Scholar
• JudsonIVerweijJGelderblomHDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialLancet Oncol201415441542324618336
   PubMed Web of Science ®Google Scholar
• TapWDJonesRLVan TineBAOlaratumab and doxorubicin versus doxorubicin alone for treatment of soft tissue sarcomas: an open label phase 1b and randomised phase 2 trialLancet20163881004348849727291997
   PubMed Web of Science ®Google Scholar
• HensleyMLBlessingJADegeestKAbulafiaORosePGHomesleyHDFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II studyGynecol Oncol2008109332332818394689
   PubMed Web of Science ®Google Scholar
• HensleyMLBlessingJAMannelRRosePGFixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trialGynecol Oncol2008109332933418534250
   PubMed Web of Science ®Google Scholar
• PautierPFloquetAPenelNRandomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study)Oncologist20121791213122022907974
   PubMed Web of Science ®Google Scholar
• HensleyMLMillerAO’MalleyDMRandomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group studyJ Clin Oncol201533101180118525713428
   PubMed Web of Science ®Google Scholar
• SeddonBMWhelanJStraussJSA prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first-line treatment in treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomasJ Clin Oncol201533Suppl abstract 10500
   Google Scholar
• CasperESWaltzmanRJSchwartzGKPhase II trial of paclitaxel in patients with soft-tissue sarcomaCancer Invest19981674424469774950
   PubMed Web of Science ®Google Scholar
• PenelNBuiBNBayJOPhase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX StudyJ Clin Oncol200826325269527418809609
   PubMed Web of Science ®Google Scholar
• SchlemmerMReichardtPVerweijJPaclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma groupEur J Cancer200844162433243618771914
   PubMed Web of Science ®Google Scholar
• FataFO’ReillyEIlsonDPaclitaxel in the treatment of patients with angiosarcoma of the scalp or faceCancer199986102034203710570428
   PubMed Web of Science ®Google Scholar
• SkubitzKMHaddadPAPaclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcomaCancer2005104236136615948172
   PubMed Web of Science ®Google Scholar
• NaganoTYamadaYIkedaTKankiHKamoTNishigoriCDocetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patientsCancer2007110364865117582627
   PubMed Web of Science ®Google Scholar
• Ray-CoquardILDomontJTresch-BruneelEPaclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized Phase II trialJ Clin Oncol201533252797280226215950
   PubMed Web of Science ®Google Scholar
• MirODomontJCioffiAFeasibility of metronomic oral cyclo-phosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcomaEur J Cancer201147451551921251814
   PubMed Web of Science ®Google Scholar
• SharmaSTakyarSMansonSCPowellSPenelNEfficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic reviewBMC Cancer20131338523937858
   PubMed Web of Science ®Google Scholar
• TascilarMLoosWJSeynaeveCVerweijJSleijferSThe pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomasOncologist200712111351136018055856
   PubMed Web of Science ®Google Scholar
• LoriganPVerweijJPapaiZPhase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European organisation for research and treatment of cancer soft tissue and bone sarcoma group studyJ Clin Oncol200725213144315017634494
   PubMed Web of Science ®Google Scholar
• SleijferSOualiMvan GlabbekeMPrognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG)Eur J Cancer2010461728319853437
   PubMed Web of Science ®Google Scholar
• Martin-LiberalJAlamSConstantinidouAClinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcomaSarcoma2013201386897324369450
   PubMedGoogle Scholar
• PatelSRGandhiVJenkinsJPhase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulationJ Clin Oncol200119153483348911481354
   PubMed Web of Science ®Google Scholar
• HartmannJTOechsleKHuoberJAn open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcomaInvest New Drugs200624324925316133789
   PubMed Web of Science ®Google Scholar
• SvancarovaLBlayJYJudsonIRGemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEur J Cancer200238455655911872349
   PubMed Web of Science ®Google Scholar
• FerraresiVCiccareseMCercatoMCGemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II studyCancer Chemother Pharmacol200863114915518351342
   PubMed Web of Science ®Google Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]J Clin Oncol200725192755276317602081
   PubMed Web of Science ®Google Scholar
• BuesaJMMouridsenHTvan OosteromATHigh-dose DTIC in advanced soft-tissue sarcomas in the adult. A phase II study of the E.O.R.T.C. Soft Tissue and Bone Sarcoma GroupAnn Oncol1991243073091868027
   PubMed Web of Science ®Google Scholar
• Garcia-Del-MuroXLopez-PousaAMaurelJRandomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas studyJ Clin Oncol201129182528253321606430
   PubMed Web of Science ®Google Scholar
• LosaRFraJLopez-PousaAPhase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomasCancer Chemother Pharmacol200759225125916736150
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMJonesRLEfficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a Phase III randomized multicenter clinical trialJ Clin Oncol201634878679326371143
   PubMed Web of Science ®Google Scholar
• SchoffskiPChawlaSMakiRGEribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialLancet2016387100281629163726874885
   PubMed Web of Science ®Google Scholar
• CuevasCFranceschADevelopment of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problemNat Prod Rep200926332233719240944
   PubMed Web of Science ®Google Scholar
• D’IncalciMBadriNGalmariniCMAllavenaPTrabectedin, a drug acting on both cancer cells and the tumour microenvironmentBr J Cancer2014111464665024755886
   PubMed Web of Science ®Google Scholar
• LarsenAKGalmariniCMD’IncalciMUnique features of trabectedin mechanism of actionCancer Chemother Pharmacol20167766367126666647
   PubMed Web of Science ®Google Scholar
• Di GiandomenicoSFrapolliRBelloEMode of action of trabectedin in myxoid liposarcomasOncogene201433445201521024213580
   PubMed Web of Science ®Google Scholar
• GroharPJGriffinLBYeungCEcteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cellsNeoplasia201113214515321403840
   PubMed Web of Science ®Google Scholar
• GroharPJSegarsLEYeungCDual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growthClin Cancer Res20142051190120324277455
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065
   PubMed Web of Science ®Google Scholar
• Bui-NguyenBButrynskiJEPenelNA phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trialEur J Cancer201551101312132025912752
   PubMed Web of Science ®Google Scholar
• ForouzeshBHidalgoMChuQPhase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignanciesClin Cancer Res200915103591359919417019
   PubMed Web of Science ®Google Scholar
• Summary of product characteristics Trabectedin Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdfAccessed July 25, 2016
   Google Scholar
• Le CesneABlayJYDomontJInterruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trialLancet Oncol201516331231925680558
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGMakiRGEcteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic studyJ Clin Oncol200523245484549216110008
   PubMed Web of Science ®Google Scholar
• MonkBJBlessingJAStreetDGMullerCYBurkeJJHensleyMLA phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group studyGynecol Oncol20121241485221996263
   PubMed Web of Science ®Google Scholar
• BlayJYLeahyMGNguyenBBRandomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasEur J Cancer20145061137114724512981
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJYJudsonIPhase II study of ET-743 in advanced soft tissue sarcomas: a European organisation for the research and treatment of cancer (EORTC) soft tissue and bone sarcoma group trialJ Clin Oncol200523357658415659504
   PubMed Web of Science ®Google Scholar
• YovineARiofrioMBlayJYPhase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patientsJ Clin Oncol200422589089914990645
   PubMed Web of Science ®Google Scholar
• Paz-AresLLopez-PousaAPovedaATrabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneInvest New Drugs201230272974020960029
   PubMed Web of Science ®Google Scholar
• Garcia-CarboneroRSupkoJGManolaJPhase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapyJ Clin Oncol20042281480149015084621
   PubMed Web of Science ®Google Scholar
• KawaiAArakiNSugiuraHTrabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 studyLancet Oncol201516440641625795406
   PubMed Web of Science ®Google Scholar
• SamuelsBLChawlaSPatelSClinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program studyAnn Oncol20132461703170923385197
   PubMed Web of Science ®Google Scholar
• SessaCPerottiANoberascoCPhase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancerEur J Cancer20094571153116119114300
   PubMed Web of Science ®Google Scholar
• BlayJYvon MehrenMSamuelsBLPhase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcomaClin Cancer Res200814206656666218927308
   PubMed Web of Science ®Google Scholar
• PautierPFloquetAChevreauCTrabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trialLancet Oncol201516445746425795402
   PubMed Web of Science ®Google Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• KasperBReichardtPPinkDCombination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG)Mar Drugs201513137938825591040
   PubMed Web of Science ®Google Scholar
• UedaTKakunagaSAndoMPhase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-hour continuous infusion in Japanese patients with soft tissue sarcomaInvest New Drugs201432469169924696229
   PubMed Web of Science ®Google Scholar